These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 39379885)

  • 1. Efficacy and safety of a lipid-containing artificial tear compared with a non-lipid containing tear: a randomized clinical trial.
    Donnenfeld E; Coats J; Barbour K; Ryan R; Joshi NR; Periman LM
    BMC Ophthalmol; 2024 Oct; 24(1):442. PubMed ID: 39379885
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy, safety, and acceptability of a lipid-based artificial tear formulation: a randomized, controlled, multicenter clinical trial.
    Simmons PA; Carlisle-Wilcox C; Chen R; Liu H; Vehige JG
    Clin Ther; 2015 Apr; 37(4):858-68. PubMed ID: 25659956
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Autologous serum eye drops for dry eye.
    Pan Q; Angelina A; Marrone M; Stark WJ; Akpek EK
    Cochrane Database Syst Rev; 2017 Feb; 2(2):CD009327. PubMed ID: 28245347
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of an enhanced viscosity artificial tear for moderate to severe dry eye disease: A multicenter, double-masked, randomized 30-day study.
    Lievens C; Berdy G; Douglass D; Montaquila S; Lin H; Simmons P; Carlisle-Wilcox C; Vehige J; Haque S
    Cont Lens Anterior Eye; 2019 Aug; 42(4):443-449. PubMed ID: 30573298
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of laughter exercise versus 0.1% sodium hyaluronic acid on ocular surface discomfort in dry eye disease: non-inferiority randomised controlled trial.
    Li J; Liao Y; Zhang SY; Jin L; Congdon N; Fan Z; Zeng Y; Zheng Y; Liu Z; Liu Y; Liang L
    BMJ; 2024 Sep; 386():e080474. PubMed ID: 39260878
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Topical cyclosporine A therapy for dry eye syndrome.
    de Paiva CS; Pflugfelder SC; Ng SM; Akpek EK
    Cochrane Database Syst Rev; 2019 Sep; 9(9):CD010051. PubMed ID: 31517988
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Study design and baseline findings from the progression of ocular findings (PROOF) natural history study of dry eye.
    McDonnell PJ; Pflugfelder SC; Stern ME; Hardten DR; Conway T; Villanueva L; Hollander DA
    BMC Ophthalmol; 2017 Dec; 17(1):265. PubMed ID: 29284427
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and Safety of a Water-Free Topical Cyclosporine, 0.1%, Solution for the Treatment of Moderate to Severe Dry Eye Disease: The ESSENCE-2 Randomized Clinical Trial.
    Akpek EK; Wirta DL; Downing JE; Tauber J; Sheppard JD; Ciolino JB; Meides AS; Krösser S
    JAMA Ophthalmol; 2023 May; 141(5):459-466. PubMed ID: 37022717
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the clinical effects of carbomer-based lipid-containing gel and hydroxypropyl-guar gel artificial tear formulations in patients with dry eye syndrome: a 4-week, prospective, open-label, randomized, parallel-group, noninferiority study.
    Wang TJ; Wang IJ; Ho JD; Chou HC; Lin SY; Huang MC
    Clin Ther; 2010 Jan; 32(1):44-52. PubMed ID: 20171410
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of a formulated eye drop with
    Tan J; Jia T; Liao R; Stapleton F
    Br J Ophthalmol; 2020 Oct; 104(10):1373-1377. PubMed ID: 31949092
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lifitegrast Ophthalmic Solution 5.0% versus Placebo for Treatment of Dry Eye Disease: Results of the Randomized Phase III OPUS-2 Study.
    Tauber J; Karpecki P; Latkany R; Luchs J; Martel J; Sall K; Raychaudhuri A; Smith V; Semba CP;
    Ophthalmology; 2015 Dec; 122(12):2423-31. PubMed ID: 26365210
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Application frequency - key indicator for the efficiency of severe dry eye disease treatment - evidence for the importance of molecular weight of hyaluronan in lubricating agents.
    Medic N; Boldin I; Berisha B; Matijak-Kronschachner B; Aminfar H; Schwantzer G; Müller-Lierheim WGK; van Setten GB; Horwath-Winter J
    Acta Ophthalmol; 2024 Aug; 102(5):e663-e671. PubMed ID: 38131131
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of a fixed combination of 0.09 % xanthan gum/0.1 % chondroitin sulfate preservative free vs polyethylene glycol/propylene glycol in subjects with dry eye disease: a multicenter randomized controlled trial.
    Pérez-Balbuena AL; Ochoa-Tabares JC; Belalcazar-Rey S; Urzúa-Salinas C; Saucedo-Rodríguez LR; Velasco-Ramos R; Suárez-Sánchez RG; Rodríguez-Carrizalez AD; Oregón-Miranda AA
    BMC Ophthalmol; 2016 Sep; 16(1):164. PubMed ID: 27645318
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy in patients with dry eye after treatment with a new lubricant eye drop formulation.
    Davitt WF; Bloomenstein M; Christensen M; Martin AE
    J Ocul Pharmacol Ther; 2010 Aug; 26(4):347-53. PubMed ID: 20653478
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Water-Free Cyclosporine Ophthalmic Solution vs Vehicle for Dry Eye Disease: A Randomized Clinical Trial.
    Peng R; Jie Y; Long Q; Gong L; Zhu L; Zhong X; Zhao S; Yan X; Gu H; Wu H; Li G; Zhang K; Krösser S; Xu R; Hong J
    JAMA Ophthalmol; 2024 Apr; 142(4):337-343. PubMed ID: 38451509
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of novel lipid-based eye drops with aqueous eye drops for dry eye: a multicenter, randomized controlled trial.
    Simmons PA; Carlisle-Wilcox C; Vehige JG
    Clin Ophthalmol; 2015; 9():657-64. PubMed ID: 25931806
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Can the optimum artificial tear treatment for dry eye disease be predicted from presenting signs and symptoms?
    Essa L; Laughton D; Wolffsohn JS
    Cont Lens Anterior Eye; 2018 Feb; 41(1):60-68. PubMed ID: 28811095
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Perfluorohexyloctane Eye Drops for Dry Eye Disease Associated With Meibomian Gland Dysfunction in Chinese Patients: A Randomized Clinical Trial.
    Tian L; Gao Z; Zhu L; Shi X; Zhao S; Gu H; Xu G; Wang L; Dai H; Zhang H; Jin X; Ma K; Xu Y; Ma L; Pei C; Ke B; Krösser S; Zhang Y; Jie Y
    JAMA Ophthalmol; 2023 Apr; 141(4):385-392. PubMed ID: 36929413
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Phase 3, Randomized, Double-Masked Study of OTX-101 Ophthalmic Solution 0.09% in the Treatment of Dry Eye Disease.
    Goldberg DF; Malhotra RP; Schechter BA; Justice A; Weiss SL; Sheppard JD
    Ophthalmology; 2019 Sep; 126(9):1230-1237. PubMed ID: 30965064
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of corneal nerve density on the response to treatment in dry eye disease.
    Kheirkhah A; Dohlman TH; Amparo F; Arnoldner MA; Jamali A; Hamrah P; Dana R
    Ophthalmology; 2015 Apr; 122(4):662-8. PubMed ID: 25542519
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.